ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

RLAY vs TARS // FORWARD P/E MULTIPLE

Relay Therapeutics Inc. (NASDAQ) VS. Tarsus Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: RLAY 2 — TARS 6
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RLAY VS. TARS) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC RLAY TARS SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -24.10% -10.90 TARS /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -5.53% -0.61% -4.92 TARS /fcf-yield <GO>
Operating Margin -60.00% -15.70% -44.30 TARS /operating-margins <GO>
Net Profit Margin -60.00% -14.60% -45.40 TARS /net-margins <GO>
Revenue Growth (YoY) 53.40% 146.70% -93.30 TARS /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 10.19 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 4/9 5/9 -1.00 TARS /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 57.2 53.4 +3.80 RLAY /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple ACTIVE — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $4.27B $3.66B $608.4M RLAY /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR RLAY REV TARS REV RLAY GROSS % TARS GROSS % RLAY FCF TARS FCF
FY 2025 $15.4M $451.4M — — -$235.9M -$22.3M
FY 2024 $10.0M $183.0M — — -$251.1M -$84.6M
FY 2023 $25.5M $17.4M — — -$300.3M -$117.5M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RLAY // BETA —
TARS // BETA —